Vacuum extraction of the mammary fibroadenomata and relapse prevention through hormonal therapy
Two groups of women with fibroadenomata of breast are examined and treated. In the core group (26 patients) low-dose monophasic combination oral contraceptives with the ethinylestrachol as an active ingredient at a dose of 20 mcg is prescribed for the period of six months after the surgical treatment. In the group of comparison (22 patients) hormonotherapy during the post-operative period does not carried out. The observing time after the operation lasted in average two and a half years. For the two check points the date of the access and the six months after the adenomammectomy are chosen. During this time the laboratory, breast ultrasound and the clinical forms of control of the condition of the mammary gland and of the hormonal background are carried out. The hormonal therapy contributed to the normalization of the hormone level of the male and female sex hormones after the adenomammectomy by means of the aspiration technique. It also contributed to a significant reduction in the risk of the recurrence and the development of new fibroadenomata of breast.